Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.
Teyssonneau D, Thiery-Vuillemin A, Dariane C, Barret E, Beauval JB, Brureau L, Créhange G, Fiard G, Fromont G, Gauthé M, Ruffion A, Renard-Penna R, Mathieu R, Sargos P, Rouprêt M, Ploussard G, Roubaud G, On Behalf Of The Cc-Afu Cancerology Committee Of The Association Française d'Urologie. Teyssonneau D, et al. Among authors: roubaud g. J Clin Med. 2022 Mar 21;11(6):1734. doi: 10.3390/jcm11061734. J Clin Med. 2022. PMID: 35330059 Free PMC article. Review.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.
Sargos P, Ferretti L, Gross-Goupil M, Orre M, Cornelis F, Henriques de Figueiredo B, Houédé N, Merino C, Roubaud G, Dallaudiére B, Richaud P, Fléchon A. Sargos P, et al. Among authors: roubaud g. Prostate Cancer Prostatic Dis. 2014 Sep;17(3):220-6. doi: 10.1038/pcan.2014.17. Epub 2014 May 6. Prostate Cancer Prostatic Dis. 2014. PMID: 24796290 Review.
[Hypofractionnated radiotherapy for elderly patients with prostate cancer].
Sargos P, Créhange G, Hennequin C, Latorzeff I, de Crevoisier R, Roubaud G, Supiot S. Sargos P, et al. Among authors: roubaud g. Cancer Radiother. 2018 Oct;22(6-7):631-634. doi: 10.1016/j.canrad.2018.07.124. Epub 2018 Aug 23. Cancer Radiother. 2018. PMID: 30145092 Review. French.
Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer.
Amestoy F, Roubaud G, Antoine M, Fonteyne V, Baumann BC, Christodouleas J, Roupret M, Azria D, Zilli T, Hennequin C, Xylinas E, Sargos P; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology. Amestoy F, et al. Among authors: roubaud g. Crit Rev Oncol Hematol. 2019 Oct;142:76-85. doi: 10.1016/j.critrevonc.2019.06.010. Epub 2019 Jul 16. Crit Rev Oncol Hematol. 2019. PMID: 31377435
98 results